BiotechTube
Home/Pipeline/Pluvicto®

Pluvicto®

Prostate Cancer

Approved / LifecycleActiveN/A

Key Facts

Indication
Prostate Cancer
Phase
Approved / Lifecycle
Status
Active
Company
Novartis

About Novartis

Novartis is a global pharmaceutical leader with a mission to reimagine medicine to improve and extend lives. With a market cap of $290.10B, it operates across 118 countries, reaching over 300 million patients annually. Its strategy focuses on delivering high-value medicines for society's greatest disease burdens through technology leadership in R&D and novel access approaches, powered by a diversified portfolio across oncology, cardiovascular, immunology, neuroscience, and rare diseases.

View full company profile

Therapeutic Areas

Cardiovascular, Renal and MetabolicImmunologyNeuroscienceOncology

Other Prostate Cancer Drugs

DrugCompanyPhase
APVO442Aptevo TherapeuticsPreclinical
APVO452Aptevo TherapeuticsDiscovery
BIO 300Humanetics Corp.Not Specified
OpaganibRedHill BiopharmaPhase 2
Small-Molecule TherapeuticAIkido LabsPre-clinical
LeronlimabCytoDynPreclinical
ENV105Kairos PharmaPhase 2
AI for Prostate CancerInvenio ImagingResearch
Mitomic™ Test for Prostate CancerMDNA Life SciencesDevelopment/Validation
Immunomodulator PlatformOmniCyteResearch
Prostate cancer 'super test'EDX MedicalDevelopment
PSMA-DexDexTech MedicalPre-clinical